Department of General Surgery, The Third Affiliated Hospital of Qiqihar Medical University, Qiqihar 161000, Heilongjiang, China.
Contrast Media Mol Imaging. 2022 Jun 23;2022:3544735. doi: 10.1155/2022/3544735. eCollection 2022.
This research aimed at exploring the improvement effect of Farnesoid X receptor (FXR) regulating bile acid (BA) on hepatocellular carcinoma with obstructive jaundice under magnetic resonance cholangiopancreatography (MRCP). Forty-eight hepatocellular carcinoma patients with obstructive jaundice who were examined in hospital were selected as the study group, and another 10 healthy volunteers who were examined at the same period were selected as the control group. The patients were treated with FXR inhibitor, and the therapeutic effect was observed. The results showed that after treatment, the AST content and TBIL content in serum of the study group were 123.5 ± 4.9 U/L and 1.8 ± 0.3 mol/L, respectively, which were significantly lower than those before treatment, 0.05; the ALT content and AST content in serum in patients with high obstruction were significantly lower than those before treatment, and the K content was significantly higher than that before treatment ( 0.05). The ALT, AST, and TBIL contents in serum in patients with low obstruction were significantly lower than those before treatment ( 0.05). Apparent diffusion coefficient (ADC) was 1.17 ± 0.49 × 10 mm/s in patients with moderate jaundice and 1.20 ± 0.27 × 10 mm/s in patients with severe jaundice, compared with that before treatment, and the difference was statistically significant ( 0.05). Based on FXR, it can regulate BA synthesis and metabolism, restore BA metabolic homeostasis, effectively play a hepatoprotective role, reduce bilirubin content in the body, and improve jaundice injury, which has application value.
本研究旨在探讨法尼醇 X 受体（FXR）调节胆汁酸（BA）对磁共振胆胰管成像（MRCP）下梗阻性黄疸肝细胞癌的改善作用。选取我院收治的 48 例梗阻性黄疸肝细胞癌患者为研究组，另选取同期健康志愿者 10 例为对照组。患者采用 FXR 抑制剂进行治疗，观察治疗效果。结果显示，治疗后，研究组患者血清 AST 含量和 TBIL 含量分别为 123.5±4.9 U/L和 1.8±0.3 μmol/L，均显著低于治疗前， 0.05；高梗阻患者血清 ALT 含量和 AST 含量均显著低于治疗前，且 K 含量显著高于治疗前， 0.05）。低梗阻患者血清 ALT、AST 和 TBIL 含量均显著低于治疗前， 0.05）。中度黄疸患者的 ADC 值为 1.17±0.49×10mm/s，重度黄疸患者的 ADC 值为 1.20±0.27×10mm/s，均明显高于治疗前，差异有统计学意义， 0.05）。基于 FXR 可以调节 BA 的合成和代谢，恢复 BA 代谢的动态平衡，有效发挥肝脏保护作用，降低体内胆红素含量，改善黄疸损伤，具有应用价值。
